Endothelial cell-specific molecule-1: a potential serum marker for gastric cancer.

No ideal serum markers for gastric cancer (GC) screening have been identified. The aim of this study was to determine the usefulness of endothelial cell-specific molecule-1 (ESM-1) as a serum marker for GC. The ESM-1 levels in serum specimens from 114 patients with GC and 55 health subjects were measured using a sandwich ELISA kit. Receiver operating characteristic (ROC) curve was calculated to assess the diagnostic value of ESM-1. Survival curves by the Kaplan-Meier method were plotted to display overall survival distributions. Univariable and multivariable Cox regression analyses were performed to assess independent prognostic factors for overall survival in GC. We showed that the ESM-1 levels in the serum of patients with GC (83.7 ± 16.2 pg/mL) were significantly elevated compared to health subjects (44.7 ± 16.4 pg/mL). The accuracy, sensitivity, and specificity of ESM-1 for GC were 0.946, 98, and 80 %, respectively, by ROC curve analysis. The positive and negative predictive values were 91 and 93.6 %, respectively. The likelihood ratios of a positive or negative test result were 20.9 and 0.14, respectively. When analyzed with a Cox regression model, a higher serum ESM-1 level (≥84.2 pg/mL) was correlated with poor prognosis. This study suggests that serum ESM-1 level is increased in patients with GC and that ESM-1 can be used as a potential serum marker for early detection and prognosis evaluation of GC.